Abstract
A new, simple and sensitive spectrofluorimetric method has been developed for the determination of oseltamivir phosphate (OSP) in capsules. The method is based on the reaction between oseltamivir and fluorescamine in borate buffer solution of pH 8.50 to give highly fluorescent derivatives that are measured at 483 nm using an excitation wavelength of 381. The different experimental parameters effecting the development and stability of the reaction product were carefully studied and optimized. The fluorescence intensity concentration plot is rectilinear over the range 50–450 ng mL−1 with a lower detection limit (LOD) of 1.219 ng mL−1 and limit of quantitation (LOQ) of 4.064 ng mL−1. Selectivity was validated by subjecting stock solution of OSP to acidic, basic, oxidative, and thermal degradation. No interference was observed from excipients present in formulations. The developed method was successfully applied to determination of the drug in capsules. The mean % recovery (n = 6) was 100.08. The results obtained were in good agreement with those obtained using a reported spectrophotometric method.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
McClellan K, Perry CM (2001) Oseltamivir: a review of its use in influenza. Drugs 61:263–283
Wiltshire H, Wiltshire B, Citron A, Clarke T, Serpe C, Gray D, Herron W (2000) Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J Chromatogr B Biomed Sci Appl 745:373–388
Dreitlein WB, Maratos J, Brocavich J (2001) Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza. Clin Ther 23:327–355. doi:10.1016/S0149-2918(01)80042-4
Nicholson KG, Aoki FY, Osterhaus ADME, Trottier S, Carewicz O, Mercier CH et al (2000) Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355:1845–1850. doi:10.1016/S0140-6736(00)02288-1
Eisenberg EJ, Cundy KC (1998) High-performance liquid chromatographic determination of GS4071, a potent inhibitor of influenza neuraminidase, in plasma by precolumn fluorescence derivatization with naphthalenedialdehyde. J Chromatogr B Biomed Sci Appl 716:267–273. doi:10.1016/S0378-4347(98)00268-0
Bahrami G, Mohammadi B, Kiani A (2008) Determination of oseltamivir carboxylic acid in human serum by solid phase extraction and high performance liquid chromatography with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci 864:38–42. doi:10.1016/j.jchromb.2008.01.048
Fuke C, Ihama Y, Miyazaki T (2008) Analysis of oseltamivir active metabolite, oseltamivir carboxylate, in biological materials by HPLC-UV in a case of death following ingestion of Tamiflu. Leg Med 10:83–87. doi:10.1016/j.legalmed.2007.07.003
Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ et al (1998) Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 42:647–653
Lindegårdh N, Hanpithakpong W, Wattanagoon Y, Singhasivanon P, White NJ, Day NP (2007) Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine. J Chromatogr B Analyt Technol Biomed Life Sci 859:74–84. doi:10.1016/j.jchromb.2007.09.018
Lindegårdh N, Hien TT, Farrar J, Singhasivanon P, White NJ, Day NP (2006) A simple and rapid liquid chromatographic assay for evaluation of potentially counterfeit Tamiflu. J Pharm Biomed Anal 42:430–433. doi:10.1016/j.jpba.2006.04.028
Joseph-Charles J, Geneste C, Laborde-Kummer E, Gheyouche R, Boudis H, Dubost JP (2007) Development and validation of a rapid HPLC method for the determination of oseltamivir phosphate in Tamiflu and generic versions. J Pharm Biomed Anal 44:1008–1013. doi:10.1016/j.jpba.2007.04.002
Green MD, Nettey H, Wirtz RA (2008) Determination of oseltamivir quality by colorimetric and liquid chromatographic methods. Emerg Infect Dis 14:552–556
British Pharmacopoeia (1998) Her Majesty’s Stationery Office, London, pp 799–800
Udenfriend S, Stein S, Böhlen P, Dairman W, Leimgruber W, Weigele M (1972) Fluorescamine: a reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range. Science 178:871–872. doi:10.1126/science.178.4063.871
Bantan-Polak T, Kassai M, Grant KB (2001) A comparison of fluorescamine and naphthalene-2,3-dicarboxaldehyde fluorogenic reagents for microplate-based detection of amino acids. Anal Biochem 297:128–136. doi:10.1006/abio.2001.5338
Validation of Analytical Procedures (1996) Methodology ICH harmonised tripartite guideline having reached step 4 of the ICH process at the ICH Steering Committee Meeting on, November 6
Narasimhan B, Abida K, Srinivas K (2008) Stability indicating RP-HPLC method development and validation for oseltamivir API. Chem Pharm Bull (Tokyo) 56:413–417. doi:10.1248/cpb.56.413
Acknowledge
This work was supported by Research Fund of the Istanbul University. Project number: 478/27122005.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Aydoğmuş, Z. Simple and Sensitive Spectrofluorimetric Method for the Determination of Oseltamivir Phosphate in Capsules Through Derivatization with Fluorescamine. J Fluoresc 19, 673–679 (2009). https://doi.org/10.1007/s10895-009-0461-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10895-009-0461-3